Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It acts as an antiepileptic drug (AED) used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years and older.
## Primary Indications
Adjunctive therapy for seizures in Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
## Adult Dosing
* **Initial Dose:** 5 mg twice daily.
* **Titration:** Gradually increase dose every week based on clinical response and tolerability, not to exceed the maximum daily dose.
* **Maintenance Dose:** Typically 10 mg twice daily.
* **Maximum Daily Dose:** 20 mg twice daily (40 mg/day).
## Pediatric Dosing (2 years and older)
* **Initial Dose:** 5 mg twice daily.
* **Titration:** Gradually increase dose every week based on clinical response and tolerability, not to exceed the maximum daily dose.
* **Maintenance Dose:** Typically 10 mg twice daily.
* **Maximum Daily Dose:** 20 mg twice daily (40 mg/day).
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are established, but consider a slower titration and lower maintenance dose.
* **Renal Impairment:** Use with caution. No specific dose adjustments are established.
* **Concomitant Medications:** Consider potential interactions (see Key Drug Interactions).
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
## Adverse Effects
Common adverse effects include somnolence, decreased appetite, constipation, aggression, irritability, difficulty with coordination, and vomiting. Serious adverse effects include severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, suicidal behavior or ideation, and withdrawal symptoms upon discontinuation. Clobazam can cause dependence and withdrawal symptoms.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Clobazam is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors may increase clobazam levels, and strong CYP3A4 inducers may decrease clobazam levels.
* **CYP2C19 Substrates:** Clobazam is a CYP2C19 inhibitor. Concomitant use with CYP2C19 substrates (e.g., proton pump inhibitors) may increase their plasma concentrations.
* **CNS Depressants:** Additive CNS depressant effects may occur with alcohol, opioids, antihistamines, and other sedating medications.
## Monitoring
* Monitor for therapeutic response and adverse effects, particularly somnolence, behavioral changes, and signs of respiratory depression.
* Monitor for signs of severe skin reactions.
* Monitor for signs of withdrawal if dose is reduced or discontinued.
* Consider drug level monitoring in cases of suspected toxicity or inadequate response, though therapeutic ranges are not well-established.
## Clinical Pearls
* Taper dosage slowly upon discontinuation to minimize withdrawal symptoms.
* Advise patients and caregivers about the risk of suicidal thoughts or behavior and to report any changes immediately.
* Inform patients about the risks of driving or operating heavy machinery due to potential somnolence.
* Clobazam can cause significant sedation, especially at the start of therapy or with dose increases.
***
*Please consult the most current prescribing information for complete details and to verify this information before making clinical decisions.*
